MA35016B1 - Imidazopyridazines en gtant qu'inhibiteurs de la kinase akt - Google Patents

Imidazopyridazines en gtant qu'inhibiteurs de la kinase akt

Info

Publication number
MA35016B1
MA35016B1 MA36290A MA36290A MA35016B1 MA 35016 B1 MA35016 B1 MA 35016B1 MA 36290 A MA36290 A MA 36290A MA 36290 A MA36290 A MA 36290A MA 35016 B1 MA35016 B1 MA 35016B1
Authority
MA
Morocco
Prior art keywords
imidazopyridazines
akt inhibitors
kinase akt
kinase
inhibitors
Prior art date
Application number
MA36290A
Other languages
English (en)
Inventor
Lars Bärfacker
William Johnston Scott
Andrea Hägebarth
Stuart Ince
Hartmut Rehwinkel
Oliver Politz
Roland Neuhaus
Hans Briem
Ulf Bömer
Original Assignee
Bayer Ip Gmbh
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh, Bayer Pharma AG filed Critical Bayer Ip Gmbh
Publication of MA35016B1 publication Critical patent/MA35016B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

L'invention concerne des imidazopyridazines de la formule (I) et un procédé pour leur fabrication et leur utilisation.
MA36290A 2011-04-07 2012-04-05 Imidazopyridazines en gtant qu'inhibiteurs de la kinase akt MA35016B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161472732P 2011-04-07 2011-04-07
PCT/EP2012/056300 WO2012136776A1 (fr) 2011-04-07 2012-04-05 Imidazopyridazines en tant qu'inhibiteurs de la kinase akt

Publications (1)

Publication Number Publication Date
MA35016B1 true MA35016B1 (fr) 2014-04-03

Family

ID=45953129

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36290A MA35016B1 (fr) 2011-04-07 2012-04-05 Imidazopyridazines en gtant qu'inhibiteurs de la kinase akt

Country Status (43)

Country Link
US (2) US9206185B2 (fr)
EP (1) EP2694510B1 (fr)
JP (1) JP5906303B2 (fr)
KR (1) KR20140022057A (fr)
CN (1) CN103596957B (fr)
AP (1) AP3597A (fr)
AR (1) AR087148A1 (fr)
AU (1) AU2012238589B2 (fr)
BR (1) BR112013025777A2 (fr)
CA (1) CA2832374A1 (fr)
CL (1) CL2013002878A1 (fr)
CO (1) CO6862145A2 (fr)
CR (1) CR20130515A (fr)
CU (1) CU24263B1 (fr)
CY (1) CY1117163T1 (fr)
DK (1) DK2694510T3 (fr)
DO (1) DOP2013000226A (fr)
EA (1) EA024890B1 (fr)
EC (1) ECSP13013008A (fr)
ES (1) ES2558780T3 (fr)
GT (1) GT201300238A (fr)
HR (1) HRP20160011T1 (fr)
HU (1) HUE026323T2 (fr)
IL (1) IL228567A0 (fr)
JO (1) JO3068B1 (fr)
MA (1) MA35016B1 (fr)
ME (1) ME02316B (fr)
MX (1) MX336865B (fr)
NI (1) NI201300105A (fr)
PE (1) PE20141380A1 (fr)
PH (1) PH12013502073A1 (fr)
PL (1) PL2694510T3 (fr)
PT (1) PT2694510E (fr)
RS (1) RS54480B1 (fr)
SG (1) SG193631A1 (fr)
SI (1) SI2694510T1 (fr)
SM (1) SMT201600001B (fr)
TN (1) TN2013000400A1 (fr)
TW (1) TWI535719B (fr)
UA (1) UA111739C2 (fr)
UY (1) UY34006A (fr)
WO (1) WO2012136776A1 (fr)
ZA (1) ZA201307223B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
UA105005C2 (uk) 2008-06-16 2014-04-10 Юніверсіті Оф Теннессі Рісерч Фаундейшн Сполуки для лікування раку
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
EP3064204A1 (fr) 2010-03-01 2016-09-07 GTx, Inc. Composes pour le traitement du cancer
US11084811B2 (en) 2010-03-01 2021-08-10 Oncternal Therapeutics, Inc. Compounds for treatment of cancer
DK2694510T3 (en) * 2011-04-07 2016-01-18 Bayer Ip Gmbh IMIDAZOPYRIDAZINER AS AKT kinase inhibitors
US9370517B2 (en) * 2012-01-10 2016-06-21 Bayer Intellectual Property Gmbh Substituted pyrazolopyrimidines as Akt kinase inhibitors
EP2802586B1 (fr) * 2012-01-10 2016-05-25 Bayer Intellectual Property GmbH Imidazopyrazines substituées comme inhibiteurs de kinase akt
US20150328320A1 (en) * 2012-11-30 2015-11-19 Glaxosmithkline Llc Novel Pharmaceutical Composition
EP2964028A4 (fr) * 2013-03-05 2017-06-07 University of Tennessee Research Foundation Composés pour le traitement du cancer
WO2014158467A1 (fr) * 2013-03-12 2014-10-02 Glaxosmithkline Llc Combinaison
EP2968343A4 (fr) * 2013-03-14 2016-11-02 Epizyme Inc Polythérapie pour traiter un cancer
US10214545B2 (en) * 2014-01-09 2019-02-26 Bayer Pharma Aktiengesellschaft Amido-substituted imidazopyridazines useful in the treatment of hyper-proliferative and/or angiogenesis disorders
WO2018098411A1 (fr) * 2016-11-28 2018-05-31 Bristol-Myers Squibb Company Inhibiteurs de gsk-3
EP3453706A1 (fr) 2017-09-08 2019-03-13 Basf Se Composés pesticides de l'imizazole
GB2600384A (en) 2020-09-30 2022-05-04 Vaderis Therapeutics Ag Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL150368A0 (en) 1999-12-23 2002-12-01 Nitromed Inc Nitrosated and nitrosylated cyclooxygenase-2-inhibitors, compositions and methods of use
ATE361297T1 (de) 2000-03-31 2007-05-15 Ortho Mcneil Pharm Inc Phenyl-substituierte imidazopyridine
JP3729343B2 (ja) 2000-04-27 2005-12-21 アステラス製薬株式会社 縮合ヘテロアリール誘導体
JP2006520796A (ja) 2003-03-17 2006-09-14 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼインヒビター
AU2004233828B2 (en) 2003-04-24 2009-05-28 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
CA2534292A1 (fr) 2003-07-30 2005-02-17 Laboratorios S.A.L.V.A.T., S.A. Imidazopyrimidines substituees pour la prevention et le traitement du cancer
DE602005026509D1 (de) 2004-04-09 2011-04-07 Merck Sharp & Dohme Hemmer der akt aktivität
EP1784175A4 (fr) 2004-08-23 2009-07-22 Merck & Co Inc Inhibiteurs de l'activite de akt
CN101006062A (zh) 2004-08-24 2007-07-25 巴斯福股份公司 用作生产离子液体的起始化合物的咪唑甲基亚硫酸盐
AU2005316826A1 (en) 2004-12-15 2006-06-22 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
CN101263142A (zh) 2005-05-20 2008-09-10 阿雷生物药品公司 Raf抑制剂化合物及其使用方法
DK1898903T3 (da) 2005-06-10 2013-07-01 Merck Sharp & Dohme Inhibitorer af Akt-aktivitet
WO2007025090A2 (fr) 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibiteurs de kinase mapk/erk
PE20070978A1 (es) 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
US7530313B2 (en) 2006-05-12 2009-05-12 Day & Zimmerman, Inc. Self-destruct fuze delay mechanism
AR064010A1 (es) * 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
SG182187A1 (en) * 2007-06-08 2012-07-30 Abbott Gmbh & Co Kg 5-heteroaryl substituted indazoles as kinase inhibitors
CL2008002398A1 (es) 2007-08-14 2009-07-31 Bayer Ip Gmbh Compuestos derivados de 6-(fenil piperidina) pirimidinas fusionadas con imidazol, triazol o pirozol, inhibidores de la via pi3k/akt; composicion farmaceutica; combinacion farmaceutica; y uso de los compuestos para el tratamiento de la neoplasia benigna y/o maligna y para el cancer.
MX2010001745A (es) * 2007-08-14 2010-03-10 Bayer Schering Pharma Ag Imidazoles fusionados para el tratamiento del cancer.
WO2009086130A1 (fr) 2007-12-21 2009-07-09 Wyeth Composés d'imidazo-[1,2-b]-pyridazine comme modulateurs des récepteurs x du foie
CA2726317A1 (fr) 2008-06-03 2009-12-10 Merck Sharp & Dohme Corp. Inhibiteurs de l'activite akt
JP2011522047A (ja) 2008-06-03 2011-07-28 メルク・シャープ・エンド・ドーム・コーポレイション Ａｋｔ活性の阻害剤
AR074072A1 (es) 2008-11-11 2010-12-22 Lilly Co Eli Compuesto de imidazol -piperidin -pirrol-pirimidin-6-ona, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar el glioblastoma multiforme
PA8854101A1 (es) 2008-12-18 2010-07-27 Ortho Mcneil Janssen Pharm Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa
WO2010088177A1 (fr) 2009-02-02 2010-08-05 Merck Sharp & Dohme Corp. Inhibiteurs de l'activité d'akt
AU2010213192A1 (en) * 2009-02-13 2011-08-04 Bayer Intellectual Property Gmbh Fused pyrimidines
US8614221B2 (en) 2009-03-11 2013-12-24 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
AR076936A1 (es) 2009-06-02 2011-07-20 Vitae Pharmaceuticals Inc Inhibidores de carbamato y urea de la 11 beta hidroxiesteroide deshidrogenasa 1
EP2473495A1 (fr) * 2009-09-18 2012-07-11 Almac Discovery Limited Composés pharmaceutiques
US8975265B2 (en) 2010-07-12 2015-03-10 Bayer Intellectual Property Gmbh Substituted imidazo[1,2-a]pyrimidines and —pyridines
CA2806655A1 (fr) 2010-07-28 2012-02-02 Bayer Intellectual Property Gmbh Imidazo[1,2-b]pyridazines substituees
DK2694510T3 (en) * 2011-04-07 2016-01-18 Bayer Ip Gmbh IMIDAZOPYRIDAZINER AS AKT kinase inhibitors

Also Published As

Publication number Publication date
SI2694510T1 (sl) 2016-02-29
US9604989B2 (en) 2017-03-28
AP3597A (en) 2016-02-19
MX2013011699A (es) 2014-01-31
DOP2013000226A (es) 2013-11-15
RS54480B1 (sr) 2016-06-30
ME02316B (me) 2016-06-20
CY1117163T1 (el) 2017-04-05
PT2694510E (pt) 2016-02-08
ZA201307223B (en) 2014-12-23
CO6862145A2 (es) 2014-02-10
JP5906303B2 (ja) 2016-04-20
UY34006A (es) 2012-10-31
ES2558780T3 (es) 2016-02-08
UA111739C2 (uk) 2016-06-10
JO3068B1 (ar) 2017-03-15
AR087148A1 (es) 2014-02-26
MX336865B (es) 2016-02-04
WO2012136776A1 (fr) 2012-10-11
PE20141380A1 (es) 2014-10-18
PH12013502073A1 (en) 2014-01-13
SG193631A1 (en) 2013-11-29
JP2014510127A (ja) 2014-04-24
AU2012238589B2 (en) 2017-02-16
US9206185B2 (en) 2015-12-08
ECSP13013008A (es) 2013-12-31
SMT201600001B (it) 2016-02-25
EA024890B1 (ru) 2016-10-31
CA2832374A1 (fr) 2012-10-11
CL2013002878A1 (es) 2014-05-02
DK2694510T3 (en) 2016-01-18
EA201301130A1 (ru) 2014-07-30
TW201245204A (en) 2012-11-16
AU2012238589A1 (en) 2013-11-07
HRP20160011T1 (hr) 2016-02-12
EP2694510B1 (fr) 2015-10-14
US20140113901A1 (en) 2014-04-24
TWI535719B (zh) 2016-06-01
CN103596957B (zh) 2016-12-07
NI201300105A (es) 2014-07-14
TN2013000400A1 (en) 2015-03-30
CU24263B1 (es) 2017-07-04
PL2694510T3 (pl) 2016-03-31
CU20130135A7 (es) 2014-02-28
CR20130515A (es) 2013-12-04
EP2694510A1 (fr) 2014-02-12
HUE026323T2 (en) 2016-05-30
NZ616270A (en) 2015-09-25
AP2013007215A0 (en) 2013-10-31
IL228567A0 (en) 2013-12-31
GT201300238A (es) 2015-04-06
BR112013025777A2 (pt) 2016-12-20
CN103596957A (zh) 2014-02-19
KR20140022057A (ko) 2014-02-21
US20150368250A1 (en) 2015-12-24

Similar Documents

Publication Publication Date Title
MA35016B1 (fr) Imidazopyridazines en gtant qu'inhibiteurs de la kinase akt
MA35434B1 (fr) Amino-quinazolines en tant qu'inhibiteurs de kinase
MX339873B (es) Inhibidores de serina/treonina cinasa.
MX340756B (es) Compuestos de quinazolina como inhibidores de serina/treonina quinasa.
CO6831982A2 (es) Pirazolo[4,3-d]pirimidinas útiles como inhibidores de cinasas
TN2014000138A1 (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.
MX2014002442A (es) Inhibidores de pirrolopirazina cinasa.
HK1210174A1 (en) Serine/threonine kinase inhibitors for the treatment of hyperproliferative|diseases
MX341456B (es) Amino-quinolinas como inhibidores de cinasa.
CR20130470A (es) INHIBIDORES DE QUINASA RELACIONADOS CON PIRROLO [2,3-d]PIRIMIDINA TROMPOMIOSINA
MX344335B (es) Derivados de benzonitrilo como inhibidores de cinasa.
IN2014MN02082A (fr)
IN2014MN01521A (fr)
MX2013015308A (es) Inhibidores de proteasoma y procesos para su preparacion, purificacion y uso.
EP2718304A4 (fr) Procédé de préparation d'un copolymère éthylène- -oléfine-diène
MX349548B (es) Compuestos de tienopirimidina.
PH12014501195A1 (en) Novel 2h-indazoles as ep2, receptor antagonists
MX2013008340A (es) Novedosas 4-amino-n-hidroxi-benzamidas para el tratamiento de cancer.
IN2014DN06964A (fr)
WO2013178322A8 (fr) Dérivés de spiro-tetrahydro-benzothiophène utilisés pour traiter les maladies neurodégénératives
EP2860170A4 (fr) Procédé de préparation d'acrylate de 4-hydroxybutyle
EP2831036A4 (fr) Procédé pour la préparation d'esters alkyliques de la fluoroleucine
IN2014MN00850A (fr)
GB201107985D0 (en) Process
EP2885302A4 (fr) Procédé de préparation d'inhibiteurs de dipeptidylpeptidase